Search Results - "GEVA, R"

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients by Martin, V, Landi, L, Molinari, F, Fountzilas, G, Geva, R, Riva, A, Saletti, P, De Dosso, S, Spitale, A, Tejpar, S, Kalogeras, K T, Mazzucchelli, L, Frattini, M, Cappuzzo, F

“…Background: In metastatic colorectal cancer (mCRC), KRAS is the only validated biomarker used to select patients for administration of epidermal growth factor…”
Get full text

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010 by VAN CUTSEM, E, DICATO, M, GROTHEY, A, HALLER, D, HAUSTERMANS, K, KERR, D, NORDLINGER, B, MARSHALL, J, MINSKY, B. D, KANG, Y. K, LABIANCA, R, LORDICK, F, GEVA, R, OHTSU, A, PAVLIDIS, N, ROTH, A, ROUGIER, P, SCHMOLL, H. J, SOBRERO, A, TABERNERO, J, VAN DEVELDE, C, ZALCBERG, J, ARBER, N, BANG, Y, BENSON, A, CERVANTES, A, DIAZ-RUBIO, E, DUCREUX, M, GLYNNE-JONES, R

“…Well-recognized experts in the field of gastric cancer discussed during the 12th European Society Medical Oncology (ESMO)/World Congress Gastrointestinal…”
Get full text

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer by Garralda, E., Sukari, A., Lakhani, N.J., Patnaik, A., Lou, Y., Im, S.-A., Golan, T., Geva, R., Wermke, M., de Miguel, M., Palcza, J., Jha, S., Chaney, M., Abraham, A.K., Healy, J., Falchook, G.S.

“…Treatment options are limited for participants with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) that progressed after two or more prior…”
Get full text

Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164 by Le, D., Kavan, P., Kim, T., Burge, M., Van Cutsem, E., Hara, H., Boland, P., Van Laethem, J., Geva, R., Taniguchi, H., Crocenzi, T., Sharma, M., Atreya, C., Diaz, L., Liang, L., Marinello, P., Dai, T., O’Neill, B.

Get full text

Comparing the broad socio‐cognitive profile of youth with Williams syndrome and 22q11.2 deletion syndrome by Weisman, O., Feldman, R., Burg‐Malki, M., Keren, M., Geva, R., Diesendruck, G., Gothelf, D.

“…Background Numerous studies have assessed the socio‐cognitive profile in Williams syndrome (WS) and, independently, in 22q11.2 deletion syndrome (22q11.2DS)…”
Get full text

A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC) by Hidalgo, M., Epelbaum, R., Wolpin, B.M., Stemmer, S.M., Geva, R., Golan, T., Borazanci, E., Borad, M., Pedersen, K.S., Park, J.O., Ramirez, R., Peled, A., Lustig, T.M., Bohana Kashtan, O., Rosenfeld, O., Sorani, E., Schlienger, K., Vainstein Haras, A., Von Hoff, D.D.

Get full text

Treatments and clinical outcomes in stage II colon cancer patients with 12-gene Oncotype DX Colon Recurrence Score® assay-guided therapy: real-world data by Brenner, B., Shulman, K., Hubert, A., Man, S., Geva, R., Ben-Aharon, I., Fennig, S., Mishaeli, M., Yarom, N., Bar-Sela, G., Brenner, R., Shai, A., Baehner, F.L., Russell, C., Soussan-Gutman, L., Voet, H., Bareket-Samish, A., Liebermann, N.

“…The 12-gene Oncotype DX Colon Recurrence Score® result quantifies the recurrence risk in stage II/III colon cancer (CC). This real-world study investigated…”
Get full text

Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study by Nanda, R, Specht, J, Dees, E.C, Berger, R, Gupta, S, Geva, R, Pusztai, L, Pathiraja, K, Ray, A, Karantza, V, Buisseret, L

Get full text

Does residual microscopic disease after chemoradiotherapy for locally advanced rectal cancer translate into a good clinical outcome? by Geva, R., Davidovics, H., Soyfer, S., Pelles‐Avraham, S., Klausner, J. M., Inbar, M., Tulchinsky, H.

“…Aim This study aimed to assess the progression‐free and overall survival of patients with residual microscopic disease following neoadjuvant chemoradiotherapy…”
Get full text

Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers by Diaz, L., Marabelle, A., Kim, T.W., Geva, R., Van Cutsem, E., André, T., Ascierto, P.A., Maio, M., Delord, J-P., Gottfried, M., Guimbaud, R., Jaeger, D., Elez, E., Yoshino, T., Joe, A., Lam, B., Ding, J., Pruitt, S., Kang, S.P., Le, D.T.

Get full text

The neurocognitive outcome of IUGR children born to mothers with and without preeclampsia by Leitner, Y., Harel, S., Geva, R., Eshel, R., Yaffo, A., Many, A.

“…Objective: To examine long-term behavioral and neurodevelopmental outcome of children born growth restricted and exposed to hypertension in utero at 9 years of…”
Get full text

Verbal short-term memory span in children: long-term modality dependent effects of intrauterine growth restriction by Geva, R., Eshel, R., Leitner, Y., Fattal-Valevski, A., Harel, S.

“…Background:  Recent reports showed that children born with intrauterine growth restriction (IUGR) are at greater risk of experiencing verbal short‐term memory…”
Get full text

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009 by Van Cutsem, E., Dicato, M., Arber, N., Berlin, J., Cervantes, A., Ciardiello, F., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Geva, R., Glimelius, B., Jones, R. Glynne, Grothey, A., Gruenberger, T., Haller, D., Haustermans, K., Labianca, R., Lenz, H. J., Minsky, B., Nordlinger, B., Ohtsu, A., Pavlidis, N., Rougier, P., Schmiegel, W., Van de Velde, C., Schmoll, H. J., Sobrero, A., Tabernero, J.

“…The article summarizes the expert discussion and recommendations on the use of molecular markers and of biological targeted therapies in metastatic colorectal…”
Get full text

Isolated mild white matter signal changes in preterm infants: a regional approach for comparison of cranial ultrasound and MRI findings by Weinstein, M, Ben Bashat, D, Gross-Tsur, V, Leitner, Y, Berger, I, Marom, R, Geva, R, Uliel, S, Ben-Sira, L

“…Objective: To compare echogenicity detected using cranial ultrasound (cUS) and diffuse excessive high signal intensity (DEHSI) detected using magnetic…”
Get full text

6015 POSTER DISCUSSION An International Consortium in Chemo-refractory Metastatic Colorectal Cancer Patients Shows Cetuximab Efficacy in Patients Harboring HER2 Gene Copy Number Gain by Martin, V, Sacconi, A, Landi, L, Riva, A, Saletti, P, Geva, R, Tejpar, S, Kalogeras, K, Frattini, M, Cappuzzo, F

Get full text

The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel by FIGER, A, IRMIN, L, GEVA, R, FLEX, D, SULKES, J, SULKES, A, FRIEDMAN, E

“…Inherited predisposition occurs in 5-10% of all gastrointestinal (GI) cancer patients, but with the exception of colorectal cancer (CRC), the genes involved in…”
Get full text

Six-Year Follow-Up of Children With Intrauterine Growth Retardation: Long-Term, Prospective Study by Leitner, Yael, Fattal-Valevski, Aviva, Geva, Ronny, Bassan, Haim, Posner, Edith, Kutai, Miriam, Many, Ariel, Jaffa, Ariel J., Harel, Shaul

“…This prospective study was designed to characterize the neurodevelopmental and cognitive difficulties specific to children with intrauterine growth retardation…”
Get full text

Genetic analysis of the APC gene regions involved in attenuated APC phenotype in Israeli patients with early onset and familial colorectal cancer by FIGER, A, IRMIN, L, GEVA, R, FLEX, D, SULKES, A, FRIEDMAN, E

“…The genetic basis for the majority of early onset or non-syndromic "familial" colorectal cancer (CRC) is unknown. Attenuated APC phenotype is characterized by…”
Get full text

Neoadjuvant systemic chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis from colorectal cancer by Asher, N., Lahat, G., Geva, R.

Get full text

2073P Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN) by Geva, R., Bar-Lev Schleider, L., Kutchuk, L. Lavi, Barilier, S., Schaffer, T., Pelles-Avraham, S., Wolf, I.

Get full text